2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2366 Combination of menin inhibition with CD19 CAR T cell immunotherapy reduces regulatory T cells and strengthens anti-leukemia activity in preclinical models of infant and pediatric KMT2A-rearranged B-ALL

Luke T Hannan, BS, David J Byrwa, MD2, Burak Yuzuguldu, MD3, Md Sahidul Islam, MS4, Protyusha Dey, PhD5, Samantha M McClellan6, Diego A Barcenas-Lopez, PhD7, Jason Tong, MS8, Shubhmita Bhatnagar, PhD9, Aimee Stablewski, PhD10, Scott Olejniczak, PhD11, Mark D Long, PhD12, Terry Fry, MD13, Sarah Tasian, MD14, Lisa M Niswander, MD PhD15
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, University at Buffalo Jacobs School of Medicine, Buffalo, New York, United States
3 University at Buffalo Jacobs School of Medicine, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
13 University of Colorado School of Medicine, Aurora, Colorado, United States
14 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
15 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Introduction: Children and adults with KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-R B-ALL) are at high risk of chemo-refractory disease and relapse. Infants with KMT2A-R B-ALL fare especially poorly compared to older patients. Immunotherapeutic and molecularly-targeted approaches including CD19-targeting chimeric antigen receptor (CAR) T cells (tisagenlecleucel; CART19) and inhibitors of the leukemia-driving menin-KMT2A interaction (menin-i) ziftomenib and revumenib have shown compelling preclinical/early clinical activity in infant and pediatric patients with KMT2A-R B-ALL, although durability of remission remains a challenge with either single agent. Menin-i have recently been implicated in enhancing graft versus acute myeloid leukemia (AML) via both T cell- and AML-mediated effects (Fetsch Blood 2026). In the current studies, we sought (1) to determine if a dual approach combining B-ALL surface-targeting CART19 T cell immunotherapy with small molecule inhibition of the epigenetic adapter menin augments therapeutic efficacy in preclinical models of pediatric KMT2A-R B-ALL and (2) to understand the mechanisms underlying potential synergistic effects.

Methods and Results: Human cell line and patient-derived xenograft murine models of infant and pediatric KMT2A-R B-ALL were treated with a subcurative dose of CART19 +/- menin-i ziftomenib. Mice receiving dual therapy demonstrated improved B-ALL clearance compared to mice receiving either CART19 or ziftomenib monotherapy. Concurrent ziftomenib led to a decrease in CART19 number, raising the possibility that direct menin-i-mediated effects upon CART19 contribute to activity against KMT2A-R B-ALL. However, we did not detect a difference in expansion kinetics, CD4/CD8 ratio, or CD8+ effector/memory T cell subsets in vitro following CD3/CD28 bead stimulation of donor T cells (n=2 donors) co-incubated with menin-i ziftomenib or revumenib. Similarly, short-term CART19 in vitro cytotoxicity and interleukin-2 (IL-2)/interferon-gamma (IFNg) production (n=3 T cell donors) against KMT2A-R or KMT2A wild-type B-ALL was not altered in the presence of menin-i. In contrast, longer-term repeated in vitro exposure of CART19 with menin-i to CD19+ ALL (every 6 days for >14 days) led to decreased expansion of CAR+ T cells. Expansion was preferentially diminished in CD4+ CAR+ T cells with a significant decrease in CD4+CD25+CD127lo/- regulatory T cells (Treg). Supporting this, ziftomenib and revumenib reduced the generation of human in vitro-induced regulatory T cells (iTregs, CD4+CD25+CD127lo/-FOXP3+) from CD3/CD28 bead-stimulated naïve CD4+ T cells, with a notable decline in iTreg Ki-67 expression.

To further characterize the effects of menin-i upon CART19 in vivo, we generated single-cell RNA sequencing data from human T cells flow-sorted from KMT2A-R B-ALL PDX-bearing mice treated concurrently with CART19 +/- 7 days of menin-i ziftomenib or revumenib (n=2 T cell donors). Cell type annotation analysis revealed numerous distinct CD4+ and CD8+ T cell phenotypic states. Menin-i therapy was associated with a proportional reduction in FOXP3+ Tregs within the CD4+ T cell compartment, consistent with our immunophenotypic studies. In parallel, pseudobulk differential expression analysis revealed widespread transcriptional changes across T cell populations with menin-i treatment, indicating that menin inhibition induces functional reprogramming of T cells in vivo.

To isolate direct menin-mediated effects in T cells, we generated MEN1 KO CART19 cells via CRISPR-Cas9. MEN1 KO CART19 exhibited no difference in in vitro cytotoxicity but displayed a decrease in IL-2/IFNg production (n=3 T cell donors). MEN1 KO and control CART19 had comparable in vivo efficacy against a KMT2A-R B-ALL cell line xenograft (n=2 T cell donors). As MEN1 KO CART19 did not recapitulate the improved anti-leukemia activity observed with menin-i and CART19 co-therapy, the enhanced therapeutic efficacy of our dual approach is unlikely due to direct loss of menin within CART19, and may, in part, be attributable to attenuated Treg suppression in the CART19 product induced by drug inhibition of the KMT2A-menin interaction.  

Conclusions: This preclinical study supports superior activity of menin-i in combination with CART19 against KMT2A-R B-ALL. Importantly, our data indicate that menin-i and CART19 dual therapy leads to improved anti-leukemia efficacy that is not evident with engineered MEN1 blockade in CART19.

Luke T Hannan, BS: No relevant conflicts of interest to declare.